Study of a new pill for chronic hives despite antihistamines
Part of Immune system & allergy, Skin clinical trials.
This study tests a new oral medication (TLL-018) for people with chronic spontaneous urticaria (hives that last more than 6 weeks) who still have symptoms despite taking antihistamines. The goal is to see if the drug can reduce itching and hives better than placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had hives (itchy welts) for at least 6 months.
- You are currently taking a daily antihistamine (such as cetirizine, loratadine, or fexofenadine) but still have hives or itching.
- You have not been treated with certain medications like JAK inhibitors, other biologics, or immunosuppressants within the last few months.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study, and you agree to use contraception if you can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, TLL-018, for people with moderate-to-severe chronic hives (CSU) that don't respond well to standard antihistamines. The goal is to see if it works quickly to reduce itching and hives.
This trial tests a new medication called THB335 for people with chronic spontaneous urticaria (CSU), which causes hives and itching for months without a clear cause. The study will see if the drug can reduce hives and itching better than a placebo (a pill with no active medicine).
This study tests whether a bacterial lysate medicine (OM-85) combined with allergy medication can better control chronic hives in people whose regular allergy pills aren't working well enough. You'll be observed over time to see if this combination is safe and effective.
This trial tests a new tablet (Alpha-0261) for chronic spontaneous urticaria (long-lasting hives without a clear cause). It aims to see if the drug is safe and tolerable. Part 1 includes people with chronic hives, and Part 2 looks at how food affects the drug in healthy adults.
This trial tests an experimental drug called ICP-332 for people with chronic spontaneous urticaria (long-term hives) that is not well controlled by standard antihistamines. The goal is to see if the drug is safe and effective at reducing hives.
This trial tests a new injection (CM512) for people with chronic spontaneous urticaria, also known as chronic hives. If you have had itchy hives for at least 6 weeks despite taking regular antihistamines, this study may help find a new treatment option.
Hear when a new Chronic Spontaneous Urticaria (CSU) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.